期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 102, 期 -, 页码 73-82出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2015.11.012
关键词
Tuberculosis; BCG boost vaccine; Dual-component adjuvants; Immunomodulators; Delivery systems; Long-term memory; Mucosal adjuvants; PAMPs
资金
- European Union [643381, HEALTH-F4-2011-280873, H2020-PHC-2014-2015/H2020-PHC-2014]
- Innovation Fund Denmark [060-2009-3]
- National Institutes of Health [AI 105422]
There is an urgent need for a new and improved vaccine against tuberculosis for controlling this disease that continues to pose a global health threat. The current research strategy is to replace the present BCG vaccine or boost BCG-immunity with subunit vaccines such as viral vectored- or protein-based vaccines. The use of recombinant proteins holds a number of production advantages including ease of scalability, but requires an adjuvant inducing cell-mediated immune responses. A number of promising novel adjuvant formulations have recently been designed and show evidence of induction of cellular immune responses in humans. A common trait of effective TB adjuvants including those already in current clinical testing is a two-component approach combining a delivery system with an appropriate immunomodulator. This review summarizes the status of current TB adjuvant research with a focus on the division of labor between delivery systems and immunomodulators. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据